Reserchers say Potential therapy may treat Sudan ebola virus in future

Potential therapy may treat Sudan ebola virus in future

6:22 AM, 30th August 2014
Reserchers say Potential therapy may treat Sudan ebola virus in future
Scientists report a new potential weapon in the fight against a strain of ebola (above) that is just as deadly as the one currently devastating West Africa.

WASHINGTON DC, US: Ebola is a rare, but deadly disease that exists as five strains, none of which have approved therapies. One of the most lethal strains is the Sudan ebolavirus (SUDV). Although not the strain currently devastating West Africa, SUDV has caused widespread illness, even as recently as 2012. In a new study appearing in the journal ACS Chemical Biology, researchers now report a possible therapy that could someday help treat patients infected with SUDV.

Researcher John Dye, Sachdev Sidhu, Jonathan Lai and colleagues explained that about 50-90 per cent of ebola patients die after experiencing the typical symptoms of the disease, which include fever, muscle aches, vomiting and bleeding. Of the five known ebolaviruses, the Zaire (EBOV) and SUDV strains are the most deadly and cause the most recurring outbreaks. Many studies have focused on EBOV, the culprit of the current epidemic, but much less attention has been placed on SUDV until now. To develop a therapy for SUDV, this research team turned to an antibody that Dye’s group previously reported. The team’s antibody was directed against SUDV and was made in mice. But the human immune system could potentially recognize that antibody as foreign and ultimately get rid of it, preventing the antibody from treating the disease. To avoid this situation, they wanted to make a “humanized” version of the antibody.

In the newly published work, the team put the ebola-specific part of the mouse antibody onto a human antibody scaffold and made some changes to this molecule. They identified two versions that were able to fend off SUDV in laboratory tests on cells and in specially bred mice. “These antibodies represent strong immunotherapeutic candidates for the treatment of SUDV infection,” said the researchers.

This research, however, isn’t expected to help with the current ebola outbreak that, as of mid-August, has killed at least 1,200 people. That’s because antibodies that kill off one strain of the virus haven’t worked against other strains. The US Food and Drug Administration — which has not yet approved any ebola therapies — did allow two US aid workers infected during the current outbreak to be treated with an experimental drug, which is a cocktail of antibodies specifically targeting EBOV.


© American Chemical Society News 



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

New method to grow germanium nanowires, improves lithium ion batteries

MISSOURI, US: Researchers at Missouri University of Science and Technology have developed what they call “a simple, one-step method” to gr ...

Read more
AkzoNobel to establish new organization for performance coatings business

AMSTERDAM, THE NETHERLANDS: AkzoNobel will establish a new organization for its performance coatings business area in order to drive leading performan ...

Read more
Agrium to acquire controlling interest in Agricen

LOVELAND, US: Loveland Products, a subsidiary of Agrium and a leading global provider of high-performance crop input products and proprietary products ...

Read more
Amerigen, Ningbo Menovo to develop generic pharmaceuticals in US

LYNDHURST, US/NINGBO, CHINA: Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co Ltd have entered into a collaboration agreement ...

Read more
New method to prevent organic food fraud

WASHINGTON DC, US: A growing number of consumers are willing to pay a premium for fruits, vegetables and other foods labelled “organic,” b ...

Read more
DuPont to pay $1.275 million fine for releasing toxic substances in West Virginia

WEST VIRGINIA, US: E.I. duPont de Nemours & Company will pay a $1.275 million fine and take corrective actions at its Belle, West Virginia plant f ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X